2 ASX healthcare shares rocking higher on big news

Race Oncology Ltd (ASX: RAC)

The Race Oncology share price is currently 7.1% higher at $1.66 per share after the clinical-stage cancer drug biotech announced positive preclinical study results.

Race said bisantrene and decitabine used together had "significantly improved cancer cell killing across a broad panel of 143 tumour cell lines than either drug used alone".

The company said the results support the use of the combined drugs as a potential treatment for many cancers. These include solid tumours such as lung, prostate, pancreas, breast, and head and neck cancers.

The two drugs will be explored further in a proposed Phase 1/2 investigator-initiated AML clinical trial.

Race CEO Dr Daniel Tillett commented:

These results open exciting new treatment opportunities for both bisantrene and decitabine. While decitabine has proven its effectiveness in haematological cancers, it has not demonstrated clinical utility in solid tumours, like lung or breast cancer.

This new body of work is highly supportive of the results from the University of Newcastle in preclinical AML models using a combination of bisantrene and decitabine.

https :// www.fool. com. au/2024/05/14/2-asx-healthcare-shares-rocking-higher-on-big-news/